ライフサイエンスコーパス: retinopathy of prematurity

1 omplications, bronchopulmonary dysplasia, or retinopathy of prematurity).

2 nt in proliferative retinopathies, including retinopathy of prematurity.

3 etinal vasculature in premature infants with retinopathy of prematurity.

4 l ulceration, cytomegalovirus retinitis, and retinopathy of prematurity.

5 wide-angle retinal images from infants with retinopathy of prematurity.

6 dysplasia, periventricular leucomalacia, and retinopathy of prematurity.

7 mia in diabetes, retinal vein occlusion, and retinopathy of prematurity.

8 nd intravitreal neovascularization (IVNV) in retinopathy of prematurity.

9 out inhibiting its activity to treat IVNV in retinopathy of prematurity.

10 r stage 3+ (i.e., stage 3 with plus disease) retinopathy of prematurity.

11 means for screening diabetic retinopathy and retinopathy of prematurity.

12 e diseases, such as diabetic retinopathy and retinopathy of prematurity.

13 that these agents may be useful in treating retinopathy of prematurity.

14 nal human/murine blood vessel formation, and retinopathy of prematurity.

15 tic retinopathy, retinal vein occlusion, and retinopathy of prematurity.

16 itamin A deficiency, congenital cataract and retinopathy of prematurity.

17 an adjunct to laser for aggressive posterior retinopathy of prematurity.

18 the pathogenesis of many diseases including retinopathy of prematurity.

19 the use of adjuncts for aggressive posterior retinopathy of prematurity.

20 rate-severe chronic lung disease, and severe retinopathy of prematurity.

21 s of the retina in a standard mouse model of retinopathy of prematurity.

22 ghest risk for developing complications from retinopathy of prematurity.

23 ngoing retinal vascular development, such as retinopathy of prematurity.

24 the catastrophic vessel loss that initiates retinopathy of prematurity.

25 larization, such as diabetic retinopathy and retinopathy of prematurity.

26 ve deleterious, protective, and no effect on retinopathy of prematurity.

27 in the multicenter study of Cryotherapy for Retinopathy of Prematurity.

28 ng has been suggested as a factor in causing retinopathy of prematurity.

29 ght exposure does not alter the incidence of retinopathy of prematurity.

30 chronic lung disease, and stage 3 or higher retinopathy of prematurity.

31 ent, cognitive or language delay, and severe retinopathy of prematurity.

32 periventricular leukomalacia, and/or severe retinopathy of prematurity.

33 lasia, necrotizing enterocolitis, and severe retinopathy of prematurity.

34 retinopathy that is representative of human retinopathy of prematurity.

35 iretinal membranes, retinal detachments, and retinopathy of prematurity.

36 rescein angiograms in premature infants with retinopathy of prematurity.

37 for oxygen saturation had a reduced rate of retinopathy of prematurity (10.6% vs. 13.5%; relative ri

38 n were traumatic ocular injury (15 [22.1%]), retinopathy of prematurity (12 [17.6%]), and endophthalm

39 athy (OIR) is a well-characterized model for retinopathy of prematurity, a disorder that results from

40 In a mouse model for retinopathy of prematurity, adam15(-/-) mice had a major

41 Retinopathy of prematurity adversely affects premature i

42 vent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye.

43 dative age-related macular degeneration, and retinopathy of prematurity, among others.

44 c vitrectomy; (5) treatment of proliferative retinopathy of prematurity and (6) treatment of retinal

45 Secondary outcomes included retinopathy of prematurity and brain injury.

46 ss associated with ischemic diseases such as retinopathy of prematurity and diabetic retinopathy are

47 Ischemic retinopathies, including retinopathy of prematurity and diabetic retinopathy, are

48 These diseases include retinopathy of prematurity and diabetic retinopathy, lea

49 stating ischemia of many diseases, including retinopathy of prematurity and diabetic retinopathy.

50 are associated with retinal diseases such as retinopathy of prematurity and diabetic retinopathy.

51 might accelerate tissue revascularization in retinopathy of prematurity and in diabetic patients.

52 Small studies show an association between retinopathy of prematurity and later retinal detachment.

53 he mechanisms that underlie the formation of retinopathy of prematurity and related detachments is no

54 the factors involved in the pathogenesis of retinopathy of prematurity and related retinal detachmen

55 e the rate from the best quartile for severe retinopathy of prematurity and severe intraventricular h

56 Surgery for retinopathy of prematurity and surgery for necrotizing e

57 ment concepts for diagnosis and treatment of retinopathy of prematurity and to provide interpretation

58 role in screening for diabetic retinopathy, retinopathy of prematurity, and age-related macular dege

59 in conditions such as diabetic retinopathy, retinopathy of prematurity, and age-related macular dege

60 ion of the visual system, the development of retinopathy of prematurity, and ametropia.

61 ar hemorrhage, periventricular leucomalacia, retinopathy of prematurity, and bronchopulmonary dysplas

62 such as for diabetic retinopathy, threshold retinopathy of prematurity, and exudative macular degene

63 nship between bronchopulmonary dysplasia and retinopathy of prematurity, and may form a bridge betwee

64 (prevalence, <1%) including cardiomyopathy, retinopathy of prematurity, and neonatal thyroid disease

65 ing conditions such as diabetic retinopathy, retinopathy of prematurity, and neovascular glaucoma.

66 eneration, retinal venous occlusive disease, retinopathy of prematurity, and optical aberrations incl

67 hage, necrotizing enterocolitis, aspiration, retinopathy of prematurity, and perinatal mortality.

68 monary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, and severe intraventricular

69 otizing enterocolitis, or stage 3 or greater retinopathy of prematurity; and severe neonatal brain in

70 f life; advancements in the understanding of retinopathy of prematurity; and understanding the develo

71 ry (AOR, 0.80; 95% CI, 0.63-1.01), or severe retinopathy of prematurity (AOR, 0.78; 95% CI, 0.56-1.10

72 4; 95% CI, 1.87-2.21), and stage 3 or higher retinopathy of prematurity (aOR, 1.18; 95% CI, 1.06-1.32

73 ase (aOR, 1.36; 95% CI, 0.78-2.39) or severe retinopathy of prematurity (aOR, 1.61; 95% CI, 0.85-3.06

74 ) fibrous membranes, or aggressive posterior retinopathy of prematurity (AP-ROP).

75 ays that cause pathologic features in severe retinopathy of prematurity as it manifests in the era of

76 tamin A deficiency, perinatal infections and retinopathy of prematurity as well as specialist pediatr

77 eatment assignments assessed the infants for retinopathy of prematurity at least biweekly for up to 1

78 ined in 3 consecutive premature infants with retinopathy of prematurity at the Oxford Eye Hospital, O

79 the therapeutic value of HIF PHDi to prevent retinopathy of prematurity because it reduces oxygen-ind

80 dities, including necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia,

81 associated with serious morbidities such as retinopathy of prematurity, bronchopulmonary dysplasia,

82 In retinopathy of prematurity, capillary growth in the reti

83 The Children's Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) model uses birth w

84 and The Children's Hospital of Philadelphia Retinopathy of Prematurity (CHOP-ROP) postnatal weight g

85 The surgical management of retinopathy of prematurity continues to employ a paradig

86 nd techniques for the surgical management of retinopathy of prematurity continues to evolve and outco

87 Analysis of data from the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) and Early Treatmen

88 We also review the applications to retinopathy of prematurity, diabetic retinopathy, age-re

89 many vision-threatening diseases, including retinopathy of prematurity, diabetic retinopathy, and ag

90 Neovascular eye diseases, including retinopathy of prematurity, diabetic retinopathy, and ag

91 tigating the utility of anti-VEGF therapy in retinopathy of prematurity, diabetic retinopathy, and ne

92 in children who developed only mild forms of retinopathy of prematurity during early life.

93 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) Study and to evaluate

94 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) Study telemedicine sy

95 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) study was conducted f

96 Approaches for the Evaluation of Acute-Phase Retinopathy of Prematurity (e-ROP) study.

97 ematurity (CRYO-ROP) and Early Treatment for Retinopathy of Prematurity (ETROP) trials and the primar

98 iabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exudative age-related macula

99 s has been implicated in the pathogenesis of retinopathy of prematurity for decades.

100 medicine study) and the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study (a multicenter

101 alysis of data from the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.

102 ho undergo early screening and treatment for retinopathy of prematurity have improved long-term funct

103 The primary ocular outcome was recurrence of retinopathy of prematurity in one or both eyes requiring

104 A significant decrease in rates of retinopathy of prematurity in our post-intervention grou

105 There was no association with retinopathy of prematurity in the preterm group, which s

106 the ffERG recordings and gestational age or retinopathy of prematurity in the preterm group.

107 Retinopathy of prematurity is a disease that manifests s

108 Retinopathy of prematurity is a leading cause of childho

109 Retinopathy of prematurity is a major side effect of oxy

110 Retinopathy of prematurity is a sight-threatening compli

111 s improve the survival of premature infants, retinopathy of prematurity is emerging as a significant

112 Retinopathy of prematurity is the leading cause of child

113 gy of proliferative diabetic retinopathy and retinopathy of prematurity is the result of the ischemia

114 ne of the many controversies in the study of retinopathy of prematurity is whether hyperoxia or alter

115 opathy, age-related macular degeneration, or retinopathy of prematurity, is a leading cause of blindn

116 the mouse, like the analogous human disease retinopathy of prematurity, is an ischemic retinopathy d

117 the causative ischemia phase (hyperoxia) of retinopathy of prematurity may be of therapeutic value i

118 Older children with regressed retinopathy of prematurity may suffer from vitreous hemo

119 ocked down Muller cell-expressed VEGF in the retinopathy of prematurity model also reduced phosphoryl

120 newborn, such as bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, a

121 injury on postnatal ultrasonography, severe retinopathy of prematurity, necrotizing enterocolitis, o

122 ty at 24 months, bronchopulmonary dysplasia, retinopathy of prematurity, neurodevelopmental outcomes,

123 m, birth weight percentile, gestational age, retinopathy of prematurity occurrence, maternal age at c

124 th weight (VLBW) infants without significant retinopathy of prematurity or neurologic morbidities wer

125 macular degeneration, diabetic retinopathy, retinopathy of prematurity, or as a complication followi

126 were no differences in chronic lung disease, retinopathy of prematurity, or NDI among survivors.

127 ficant treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for zone II

128 In the oxygen-induced retinopathy model of retinopathy of prematurity, PGC-1alpha expression is dra

129 udies included low birth weight, cicatricial retinopathy of prematurity, prematurity, smoking through

130 ) has been widely used in studies related to retinopathy of prematurity, proliferative diabetic retin

131 tion underlies blinding eye diseases such as retinopathy of prematurity, proliferative diabetic retin

132 Retinopathy of prematurity recurred in 3 (14%) of 22 IVB

133 Retinopathy of prematurity recurred in 4 infants in the

134 Patients undergoing surgical repair of retinopathy of prematurity-related detachments (stage 4A

135 patent ductus arteriosus requiring surgery, retinopathy of prematurity requiring surgery, necrotizin

136 Cases involving retinopathy of prematurity resulted in the highest payme

137 s were grouped as those who were treated for retinopathy of prematurity (ROP) (ROP-Tx group); those w

138 Retinopathy of prematurity (ROP) affects only premature

139 increased neovascularization in the model of retinopathy of prematurity (ROP) and in the in vivo Matr

140 Because angiogenic abnormalities in retinopathy of prematurity (ROP) are manifested in prete

141 l trends in the diagnosis of plus disease in retinopathy of prematurity (ROP) by experts.

142 eveloped to improve diagnostic competency in retinopathy of prematurity (ROP) by ophthalmologists-in-

143 tinopathy (OIR) was generated as a model for retinopathy of prematurity (ROP) by placing 7-day-old mi

144 Regular retinal evaluation is necessary for retinopathy of prematurity (ROP) cases.

145 Retinopathy of prematurity (ROP) caused blindness in 32.

146 Retinopathy of prematurity (ROP) causes 100,000 new case

147 th factor (VEGF) agents for the treatment of retinopathy of prematurity (ROP) compared with laser pho

148 on retinal image grading of fellow eyes for retinopathy of prematurity (ROP) features (stage, zone a

149 Telemedicine in retinopathy of prematurity (ROP) has the potential for d

150 ffective treatments for potentially blinding retinopathy of prematurity (ROP) have been introduced, t

151 Detection of treatment-requiring retinopathy of prematurity (ROP) involves serial eye exa

152 Retinopathy of prematurity (ROP) is a leading cause of b

153 Retinopathy of prematurity (ROP) is a leading cause of c

154 Retinopathy of prematurity (ROP) is a major complication

155 Retinopathy of prematurity (ROP) is a potentially blindi

156 Retinopathy of prematurity (ROP) is a vision-threatening

157 reduced vision in patients with a history of retinopathy of prematurity (ROP) is not yet fully unders

158 Retinopathy of prematurity (ROP) is one of the targets f

159 Retinopathy of prematurity (ROP) is the leading cause of

160 f visual impairment/blindness as a result of retinopathy of prematurity (ROP) may rise.

161 A murine retinopathy of prematurity (ROP) model was used to exami

162 n profile of the miR-17 family in the murine retinopathy of prematurity (ROP) model, whereby Vegfa ex

163 Children born prematurely who develop retinopathy of prematurity (ROP) often develop myopia, a

164 Published definitions of plus disease in retinopathy of prematurity (ROP) reference arterial tort

165 ibed, the putative roles of these factors in retinopathy of prematurity (ROP) remain unknown.

166 Despite current treatments, retinopathy of prematurity (ROP) remains a major cause o

167 gy to identify infants needing treatment for retinopathy of prematurity (ROP) requires repeated exami

168 r pigment in premature babies at the time of retinopathy of prematurity (ROP) screening and in childr

169 undred thirty-one preterm infants undergoing retinopathy of prematurity (ROP) screenings.

170 Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevac

171 elial growth factor (VEGF) in a patient with retinopathy of prematurity (ROP) treated with ranibizuma

172 Retinal tissue from a mouse model of retinopathy of prematurity (ROP) was analyzed by RT-PCR

173 tyrosine kinase c-abl in the pathogenesis of retinopathy of prematurity (ROP) was examined using the

174 Screening for retinopathy of prematurity (ROP) was performed in the ne

175 In the 1940s and 1950s retinopathy of prematurity (ROP) was the single commones

176 A rat model of retinopathy of prematurity (ROP) was used in the in vivo

177 The neonatal mouse model of retinopathy of prematurity (ROP) was used to study the e

178 More severe stages of retinopathy of prematurity (ROP) were found among CMV-in

179 ctors, and with the presence and severity of retinopathy of prematurity (ROP) were investigated by un

180 (BRMECs) and a well-established rat model of retinopathy of prematurity (ROP) were used to investigat

181 Mouse models for retinopathy of prematurity (ROP) were used.

182 s a potentially more effective treatment for retinopathy of prematurity (ROP) with fewer acute and lo

183 scular damages are the cardinal hallmarks of retinopathy of prematurity (ROP), a leading cause of vis

184 gly important component of clinical care for retinopathy of prematurity (ROP), but little information

185 625 mg) is increasingly used to treat type 1 retinopathy of prematurity (ROP), but there remain conce

186 nt of several blinding retinopathies such as retinopathy of prematurity (ROP), diabetic retinopathy (

187 Many ocular pathologies, including retinopathy of prematurity (ROP), diabetic retinopathy,

188 ction development in children with regressed retinopathy of prematurity (ROP), including those with a

189 or periventricular leukomalacia (PIVH/PVL), retinopathy of prematurity (ROP), length of hospital sta

190 scularization in diabetic retinopathy and in retinopathy of prematurity (ROP), major causes of blindn

191 To test the hypothesis that in experimental retinopathy of prematurity (ROP), retinal neovasculariza

192 In children with a history of mild retinopathy of prematurity (ROP), test the hypothesis th

193 Retinopathy of prematurity (ROP), the most common cause

194 In a rat model of retinopathy of prematurity (ROP), the retinal vasculatur

195 DIR) in the neonatal rat, analogous to human retinopathy of prematurity (ROP), was previously describ

196 This neovascularization appears analogous to retinopathy of prematurity (ROP), which occurs in human

197 EGF Trap or hFc on P22 after confirmation of retinopathy of prematurity (ROP)-like pathology and were

198 sparing vitrectomy (LSV) surgery in advanced retinopathy of prematurity (ROP).

199 ing and diagnostic tool in the management of retinopathy of prematurity (ROP).

200 d retinal detachment in preterm infants with retinopathy of prematurity (ROP).

201 vent neovascularization in a rodent model of retinopathy of prematurity (ROP).

202 ight gain rate to predict the risk of severe retinopathy of prematurity (ROP).

203 ng in young-preterm infants without advanced retinopathy of prematurity (ROP).

204 d intravitreous neovascularization (IVNV) in retinopathy of prematurity (ROP).

205 atal weight gain is strongly associated with retinopathy of prematurity (ROP).

206 d review the recent scientific literature on retinopathy of prematurity (ROP).

207 rable than peripheral rods to the effects of retinopathy of prematurity (ROP).

208 ormalities that are the clinical hallmark of retinopathy of prematurity (ROP).

209 RTP801-knockout mice were used in a model of retinopathy of prematurity (ROP).

210 eovascularization (NV) in an animal model of retinopathy of prematurity (ROP).

211 es in basic science and clinical research on retinopathy of prematurity (ROP).

212 betic retinopathy, macular degeneration, and retinopathy of prematurity (ROP).

213 uced retinopathy which serves as a model for retinopathy of prematurity (ROP).

214 g to a vision-threatening retinopathy termed retinopathy of prematurity (ROP).

215 t retinas is analogous to clinically scoring retinopathy of prematurity (ROP).

216 : a retinal explant assay and a rat model of retinopathy of prematurity (ROP).

217 for the development of neovascularization in retinopathy of prematurity (ROP).

218 quantified and described in the dog model of retinopathy of prematurity (ROP).

219 ovascularization in the newborn rat model of retinopathy of prematurity (ROP).

220 optic components in children with or without retinopathy of prematurity (ROP).

221 f treatment strategies for the management of retinopathy of prematurity (ROP).

222 h conventional laser photoablation in type 1 retinopathy of prematurity (ROP).

223 icting associations between preeclampsia and retinopathy of prematurity (ROP).

224 strongly associated with treatment-requiring retinopathy of prematurity (ROP).

225 pendent risk factors for treatment-demanding retinopathy of prematurity (ROP).

226 tinal fundus images from infants at risk for retinopathy of prematurity (ROP).

227 n found to be effective for the treatment of retinopathy of prematurity (ROP).

228 fection more than 3 days after birth, severe retinopathy of prematurity, severe intraventricular hemo

229 onal laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit

230 omalacia, severe bronchopulmonary dysplasia, retinopathy of prematurity (stage 3 or higher), or necro

231 ., before the national screening program for retinopathy of prematurity started), and 2 151 972 were

232 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity study, conducted from May 201

233 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity Study.

234 ased the prevalence of aggressive, posterior retinopathy of prematurity that may be unresponsive to c

235 C-A37668) was investigated in a rat model of retinopathy of prematurity, to examine the roles of MMP-

236 Sensitivity for Early Treatment of Retinopathy of Prematurity type 1 ROP and potential redu

237 Retinopathy of prematurity was diagnosed in 102 infants

238 Retinopathy of prematurity was diagnosed in only two neo

239 The risk-adjusted probability of death or retinopathy of prematurity was highest among infants bor

240 al insufficiency (UPI) increases severity of retinopathy of prematurity, we developed a composite rat

241 OP and 14/55 (26%) with GA </= 32 weeks with retinopathy of prematurity were affected by strabismus.

242 their associations with gestational age and retinopathy of prematurity were examined.

243 urodevelopmental outcomes, hearing loss, and retinopathy of prematurity were similar between the 2 gr

244 have shown that infants had reduced rates of retinopathy of prematurity when lower targets of oxygen

245 ew intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels w

246 yndrome with cardiovascular development, and retinopathy of prematurity with lung development.

247 7 years old, 8 preterm and 17 with regressed retinopathy of prematurity with normal-appearing posteri

248 hat characterizes severe treatment-requiring retinopathy of prematurity, yet diagnostic agreement amo